From Surf Wiki (app.surf) — the open knowledge base
Dapagliflozin/saxagliptin
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.
| Column 1 | Column 2 |
|---|---|
| This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Dapagliflozin/saxagliptin" – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message) |
| Combination of |
|---|
| SGLT-2 inhibitor |
| Dipeptidyl peptidase-4 inhibitor |
| Qtern |
| Professional Drug Facts |
| .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0} |
| US DailyMed: Qtern |
| AU: D |
| By mouth |
| A10BD21 (WHO) |
| US: ℞-only |
| EU: Rx-only |
| 2446322-16-1 |
| D10826 |
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.
In the United States, dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes:
- to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.
- when already being treated with saxagliptin and dapagliflozin.
Ask Mako anything about Dapagliflozin/saxagliptin — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report